Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

17 June, 2022

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.

Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.

Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.

Subtypes of Alzheimer’s disease: questions, controversy, and meaning.

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.

Components of gait in people with and without mild cognitive impairment.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Blood-based biomarkers for Alzheimer’s disease.

Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

3 February, 2022

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.

30 June, 2021

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

24 June, 2021

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.

14 June, 2021

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

The global Alzheimer’s Association round robin study on plasma amyloid β methods.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Sex differences in off-target binding using tau positron emission tomography.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

A multicenter comparison of [¹⁸F]flortaucipir, [18F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [¹⁸F]flutemetamol amyloid PET images.

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.

Biomarker testing in MCI patients-deciding who to test.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

30 April, 2021

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

3 February, 2021

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.

29 January, 2021

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.

Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

28 July, 2020

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

24 July, 2020

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

14 June, 2020

Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease.

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.

Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease.

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease.

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease.

The impact of demographic, clinical, genetic, and imaging variables on tau PET status.

Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age.

Image reconstruction methods affect software-aided assessment of pathologies of [¹⁸F]flutemetamol and [¹⁸F]FDG brain-PET examinations in patients with neurodegenerative diseases.

Validation of a spatial normalization method using a principal component derived adaptive template for [¹⁸F]florbetaben PET.

Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.

The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people.

Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease.

Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers.

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

The implications of different approaches to define AT(N) in Alzheimer disease.

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.

Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

Relationship between cortical iron and tau aggregation in Alzheimer’s disease.

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease.

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment.

Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding.

Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease.

[¹⁸F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case.

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. 

Head-to-head comparison of tau positron emission tomography tracers  [¹⁸F]flortaucipir and [¹⁸F]RO948.

Apathy and anxiety are early markers of Alzheimer’s disease.

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease.

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume.

13 June, 2019

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. 

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity.

Predicting Clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. 

A quick test of cognitive speed can predict development of dementia in Parkinson’s disease. 

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. 

Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease.

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. 

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients.  

Determining clinically meaningful decline in preclinical Alzheimer disease.

Towards a unified protocol for handling of CSF before β-amyloid measurements. 

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. 

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). 

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. 

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. 

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. 

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. 

Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. 

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease. 

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia. 

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Cross-validation study of practical algorithms. 

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. 

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer’s disease. 

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. 

Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. 

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease. 

Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.

8 November, 2018

Molecular properties underlying regional vulnerability to Alzheimer’s disease pathology.

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.

Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology.

13 June, 2018

Exploring causality of the association between smoking and Parkinson’s disease.

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer’s disease.

Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.  

Parkinson’s disease: evolution of cognitive impairment and CSF Aβ_1-42 profiles in a prospective longitudinal study.  

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders.

Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study. 

Regional times to equilibria and their impact on semi-quantification of [₁₈F]AV-1451 uptake.

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer’s disease diagnosis: A Review.  

Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic Review.

Alzheimer’s Disease Neuroimaging Initiative. Amyloid pathology in the progression to mild cognitive impairment.

Altered structural network organization in cognitively normal individuals with amyloid pathology. 

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Amyloid Network Topology Characterizes the Progression of Alzheimer’s Disease During the Predementia Stages.

Amyloid blood biomarker detects Alzheimer’s disease.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease.

Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms.

18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies.  

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease. 

Alteration of putaminal fractional anisotropy in Parkinson’s disease: a longitudinal diffusion kurtosis imaging study. 

Comparing 18F-AV-1451 with CSF T-tau and P-tau for diagnosis of Alzheimer’s disease. 

16 April, 2018

CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.

Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later

Performance of Different Amyloid Immunoassays in Predicting Outcome of Visual Assessment of Amyloid PET Imaging

25 August, 2017

The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals.

27 June, 2017

Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease.

13 June, 2017

The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer’s disease.

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease. 

CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients.

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. 

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer’s Disease and Parkinsonian Disorders. 

Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. 

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity.

Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment 

Atrophy of the posterior subiculum is associated with memory impairment, tau- and Aβ pathology in non-demented individuals.

In vivo retention of (18)F-AV-1451 in corticobasal syndrome.

Distinct 18F-AV- 1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease.

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. 

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

Psychometric testing of a Swedish version of the Apathy Evaluation Scale.

Tau oligomers in cerebrospinal fluid in Alzheimer’s disease.

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.

Tau Pathology Distribution in Alzheimer’s disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks.

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder

13 March, 2017

Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregationn in Alzheimer´s disease

Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology

27 October, 2016

Plasma tau in Alzheimer disease

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

17 October, 2016

Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis?

10 October, 2016

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers.

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease.